| 0.1235 -0.014 (-10.12%) | 10-02 12:17 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.21  |
1-year : | 0.26 |
| Resists | First : | 0.18 |
Second : | 0.22 |
| Pivot price | 0.15 |
|||
| Supports | First : | 0.12 |
Second : | 0.1 |
| MAs | MA(5) : | 0.14 |
MA(20) : | 0.16 |
| MA(100) : | 0.24 |
MA(250) : | 0.33 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0.1 | D(3) : | 0.1  |
| RSI | RSI(14): 18.5 |
|||
| 52-week | High : | 0.82 | Low : | 0.12 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XAGE ] has closed below the lower bollinger band by 16.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 54.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.13 - 0.13 | 0.13 - 0.13 |
| Low: | 0.12 - 0.12 | 0.12 - 0.12 |
| Close: | 0.12 - 0.12 | 0.12 - 0.12 |
Longevity Health Holdings Inc. specializes in creating plasma-based bioactive materials (PBMs) aimed at fostering tissue regeneration and repair in response to injury, illness, and the natural aging process. The company's primary investigational product is CT-101, which acts as a powerful accelerant for bone healing in diverse applications such as tibia fracture recovery, foot/ankle and spinal fusions, serving as a dental bone graft substitute, and filling bone voids. Additionally, CT-101 functions as a tissue healing accelerant, offering potential for treating androgenetic alopecia and persistent chronic wounds. Established in 2008, the company maintains its headquarters in Pittsburgh, Pennsylvania.
Thu, 01 Oct 2026
Longevity Health Holdings, Inc. (OTC: XAGE) Share Price, XAGE Stock News, XAGE Share Price & Updates - kalkine.ca
Tue, 08 Sep 2026
Longevity Health Holdings Enters into Securities Purchase Agreement for Up to $625,000 in Gross Proceeds - Yahoo Finance
Mon, 17 Aug 2026
Longevity Health Holdings Announces Settlement of Litigation with Puritan Partners LLC - Yahoo Finance
Fri, 14 Aug 2026
Longevity Health Holdings, Inc. (NASDAQ: XAGE) Share Price, XAGE Stock News, XAGE Share Price & Updates - kalkine.ca
Tue, 17 Mar 2026
Longevity Health Holdings Closes Strategic Investment and - GlobeNewswire
Mon, 14 Jul 2025
Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 36 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -3.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.24 |
| Profit Margin | 0 % |
| Operating Margin | -192.7 % |
| Return on Assets (ttm) | -158.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -21.4 % |
| Gross Profit (p.s.) | 0.29 |
| Sales Per Share | 0.68 |
| EBITDA (p.s.) | -2.43 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -2 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -0.04 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 0.18 |
| Price to Cash Flow | -0.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|